China's Particle Therapy Equipment Market
Opportunities Outweigh Challenges
Bibliographic Data
| ID | 22069754 |
|---|---|
| Authors | Zhongying Dai (Chinese Academy of Sciences), Yuanyuan Ma (0000-0002-1090-4551, Chinese Academy of Sciences), Qiang Li (0000-0003-2737-0768, Chinese Academy of Sciences, corresponding author) |
| Year | 2020 |
| Volume | 8 |
| Pages | 602776-602776 |
| Publication date | 2020-12-01 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Public Health (JOURNAL) |
| Journal identifiers | ISSN: 2296-2565 • E-ISSN: 2296-2565 |
| Publisher | Frontiers Media SA (PUBLISHER • CH) |
| DOI | 10.3389/fpubh.2020.602776 |
| PMID | 33335881 |
| OpenAlex | W3108725261 |
| Language | EN |
| References cited | 6 |
Since 2019, China has been the second largest medical device market in the world. At present, high-end radiotherapy equipment such as particle therapy system has a huge market potential due to the grim situation of cancer prevention and control and the growth of people's wealth in China. However, China's MedTech industry, especially the particle therapy equipment field, still faces the influence of policy, fluctuation of market demand, strengthening of industry supervision, and even geopolitical realities. This paper reviews the market prospect of particle therapy medical devices from the perspective of China's medical device policy and demand information analysis, which is conducive to the research on the industrial layout of particle therapy medical physics, and also helps high-performance medical device manufacturers to expand their business visions. MedTech manufacturers should actively adjust their business strategy and implement scientific and technological innovation on the basis of compliance with industry regulatory requirements in order to seize opportunities from challenges and gain profits growth
Business · China · Economics · Geopolitics · Industrial organization · Political science · Supply and demand · Vision · Global Health Care Issues · Health Systems, Economic Evaluations, Quality of Life · Healthcare Systems and Reforms · Finance
| Highly cited | No |
|---|